A. Young

Followers

Following

Co-authors

Public Views

Allan H. Young, MB, ChB, MPhil, PhD, FRCP (Edin.), FRCPC, [email protected] Allan Young holds the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London (where he is also interim Vice-Dean for Academic Psychiatry), United Kingdom (UK). Prof Young is the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) Cluster and Theme lead in the Translational Therapeutics Cluster. Prof Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic. He has held academic appointments at Oxford University

less

Dayalan Sampath

Texas A&M University

Elliot Clayton Brown

Charité - Universitätsmedizin Berlin / Charité Medical University Berlin

Fabio Yamamoto

Universidade de São Paulo

Luisa Terroni

Dan Iosifescu

Union Graduate College-Icahn School of Medicine at Mount Sinai Bioethics Program

Adriana Conforto

Universidade de São Paulo

Filomeno Cortese

University of Calgary

Etienne Sibille

University of Toronto

David Vago

Vanderbilt University

Amit Anand

Case Western Reserve University

Interests

Uploads

Papers by A. Young

Diagnostic and therapeutic utility of neuroimaging in depression: an overview

by Anthony Cleare and A. Young

Neuropsychiatric Disease and Treatment, 2014

A growing number of studies have used neuroimaging to further our understanding of how brain stru... more A growing number of studies have used neuroimaging to further our understanding of how brain structure and function are altered in major depression. More recently, these techniques have begun to show promise for the diagnosis and treatment of depression, both as aids to conventional methods and as methods in their own right. In this review, we describe recent neuroimaging findings in the field that might aid diagnosis and improve treatment accuracy. Overall, major depression is associated with numerous structural and functional differences in neural systems involved in emotion processing and mood regulation. Furthermore, several studies have shown that the structure and function of these systems is changed by pharmacological and psychological treatments of the condition and that these changes in candidate brain regions might predict clinical response. More recently, "machine learning" methods have used neuroimaging data to categorize individual patients according to their diagnostic status and predict treatment response. Despite being mostly limited to group-level comparisons at present, with the introduction of new methods and more naturalistic studies, neuroimaging has the potential to become part of the clinical armamentarium and may improve diagnostic accuracy and inform treatment choice at the patient level.

Download

PMH21 INPATIENT MEDICATION UTILIZATION AND COSTS OF RISPERIDONE, OLANZAPINE AND QUETIAPINE: A RETROSPECTIVE CHART ABSTRACTION STUDY

by A. Young and Alan Swann

Value in Health, 2002